CNS Pharmaceuticals (NASDAQ: CNSP), a biopharmaceutical company focused on developing novel treatments for cancers of the brain and central nervous system, has announced its participation in the LIVE! with Webull Corporate Connect: Virtual Biotech Investment WebinarThe event is planned for Wednesday, August 28, 2024, 3:20 p.m. ET.
John Climaco, the company’s CEO, will present and discuss current company developments during the webinar. This presentation will provide investors and interested parties with the opportunity to gain insight into CNS Pharmaceuticals’ latest advances and future plans in the field of cancer treatment.
Attendees can register for the event using the registration link provided to join the live webcast and learn more about CNS Pharmaceuticals’ innovative approaches to treating primary and metastatic brain and central nervous system cancers.
CNS Pharmaceuticals (NASDAQ: CNSP), a biopharmaceutical division focused on developing new treatments for brain and central nervous system tumors, has announced its participation in all LIVE! with Webull Corporate Connect: Virtual Webinar on Biotech Investing. The event is planned for Wednesday, August 28, 2024, 3:20 p.m. ET.
John Climaco, CEO, moderator and panelist, spoke to recent event attendees during the webinar. This presentation provides opportunities for investors and offers interesting information about CNS Pharmaceuticals’ recent progress and future prospects in the field of tumor treatment.
I am attending the registration sites to enter the formal registration link, agree to the university, broadcast the live webcast, and learn more about my new innovations from CNS Pharmaceuticals to attack primary tumors and metastases in the cervix and central nervous system.
CNS Pharmaceuticals (NASDAQ: CNSP), a biopharmaceutical company involved in the development of innovative treatments for brain cancer and the central system, has announced its participation in the University LIVE! with Webull Corporate Connect: Virtual Webinar on Inversion and Biotechnology. The event is programmed for Wednesday, August 28, 2024, at 3:20 p.m. ET.
John Climaco, Executive Director of the Company, presented and discussed the Company’s recent employees during the webinar. This presentation provides investors and interested parties with an opportunity to obtain information on CNS Pharmaceuticals’ latest advances and future plans in the field of cancer treatment.
Attendees can register for the event to experience in vivo translation and learn more about CNS Pharmaceuticals’ innovative technologies to treat primary and metastatic cancers in the brain and systemic o central.
CNS Pharmaceuticals (NASDAQ: CNSP), 라이브! 웹울과 함께하는 연업 연결: 밀상 생명공학 투자 웨비나에 참여한다고 발표했습니다. 이 행사는 8. September 28, 2024, 3. September 20 ETI never made it.
The CEO has decided on the future. I have the experience that CNS Pharmaceuticals has had a new experience in this area. 대한 통찰력을 제공할 기회를 제공합니다.
I’m not a fan of this product, I’m a professional. I’m a professional The company CNS Pharmaceuticals has chosen to cooperate with CNS Pharmaceuticals. I took the time to waste my time.
CNS Pharmaceuticals (NASDAQ: CNSP), a biopharmaceutical company specializing in the development of new traits for cervical cancer and the central nervous system, has announced its participation LIVE! with Webull Corporate Connect: Virtual Investment Webinar in Biotechnology. The event is planned for you Friday, August 28, 2024, 3:20 p.m. ET.
John Climaco, CEO of the Company, will present and discuss the Company’s latest developments in a webinar. This presentation will provide investors and interested parties with an opportunity to receive information about CNS Pharmaceuticals’ current progress and future plans in the field of cancer.
Attendees can register prior to the event via the registration lien, they can access the webinar directly and learn about CNS Pharmaceuticals’ innovative approaches to detect primary and metastatic cancers in cervical and central nervous system.
CNS Pharmaceuticals (NASDAQ: CNSP), a biopharmaceutical company focused on developing novel treatments for brain and central nervous system tumors, announced its participation in the LIVE! with Webull Corporate Connect: Virtual Biotech Investment Webinar The event is for Wednesday, August 28, 2024, at 3:20 p.m. ET set.
John Climaco, the Company’s Chief Executive Officer, will present and discuss recent company developments during the webinar. This presentation will provide investors and interested parties with an opportunity to gain insight into CNS Pharmaceuticals’ latest advances and future plans in the field of cancer treatment.
Attendees can register for the event using the registration link provided to engage with the live webcast and learn more about CNS Pharmaceuticals’ innovative approaches to combating primary and metastatic tumors in the brain and central nervous system.
Live webcast on Wednesday, August 28th at 3:20 p.m. ET
HOUSTON, TX / ACCESSWIRE / August 27, 2024 / CNS Pharmaceuticals, Inc. (NASDAQ:CNSP) (“CNS” or the “Company”), a biopharmaceutical company focused on developing novel treatments for primary and metastatic cancers of the brain and central nervous system, today announced that John Climaco, Chief Executive Officer of CNS Pharmaceuticals, will present and discuss current company events at LIVE! with Webull Corporate Connect: Virtual Biotech Investment Webinar on Wednesday, August 28, 2024 at 3:20 p.m. ET.
Conference details:
Conference: LIVE! with Webull Corporate Connect: Virtual Biotech Investment Webinar
Date/Time: Wednesday, August 28, 2024, 3:20 p.m. ET
Moderator: John Climaco, Chairman of the Board
Registration link: HERE
About Webull Financial
Webull Financial is a leading online brokerage platform dedicated to empowering self-reliant investors with innovative tools and cutting-edge technology. With low-cost trading across a wide range of assets, advanced charting tools, and real-time market data, Webull is revolutionizing the way individuals approach investing. Its user-centric approach and commitment to staying at the forefront of industry trends underscore its mission to provide a seamless and rewarding experience for traders of all levels. Through the Webull Group, Webull Financial and its subsidiaries collectively serve tens of millions of users from over 180 countries worldwide. Securities and futures trading is offered to clients of Webull Financial LLC (“Webull Financial”), a broker-dealer registered with the Securities and Exchange Commission (SEC) and a futures commission dealer registered with the Commodity Futures Trading Commission (CFTC). Webull Financial is a member of the Financial Industry Authority (FINRA), the National Futures Association (NFA), and the Securities Investor Protection Corporation (SIPC). All investments involve risk, including the possible loss of principal. For more information about Webull, visit www.webull.com.
About CNS Pharmaceuticals, Inc.
CNS Pharmaceuticals is a clinical-stage pharmaceutical company developing a series of cancer drug candidates for the treatment of primary and metastatic cancers of the brain and central nervous system. The company’s lead drug candidate, Berubicin, is a novel anthracycline and the first anthracycline that appears to cross the blood-brain barrier. Berubicin is currently being developed to treat a number of serious brain and CNS oncology indications, including glioblastoma multiforme (GBM), an aggressive and incurable form of brain cancer.
For more information, visit www.CNSPharma.com. You can also connect with the company on X, Facebook and LinkedIn.
CONTACTS:
Investor Relations Contact
JTC Team, LLC
Jenne Thomas
833-475-8247
[email protected]
SOURCE: CNS Pharmaceuticals, Inc.
View the original press release on accesswire.com.
Frequently Asked Questions
When is CNS Pharmaceuticals (CNSP) presenting at the Webull Corporate Connect webinar?
CNS Pharmaceuticals (CNSP) will present at the LIVE! with Webull Corporate Connect: Virtual Biotech Investment Webinar on Wednesday, August 28, 2024, at 3:20 p.m. ET.
Who will present at the Webull Corporate Connect webinar for CNS Pharmaceuticals (CNSP)?
John Climaco, Chief Executive Officer of CNS Pharmaceuticals (CNSP), will present and discuss current company events in the Webull Corporate Connect webinar.
What is the focus of CNS Pharmaceuticals’ (CNSP) research and development?
CNS Pharmaceuticals (CNSP) specializes in the development of novel treatments for primary and metastatic cancers of the brain and central nervous system.
How can investors participate in CNS Pharmaceuticals’ (CNSP) presentation at the Webull Corporate Connect webinar?
Investors can participate by registering for the event using the registration link provided, which will enable them to join the live webcast on August 28, 2024.
